Predicting Time to Nursing Home Care and Death in Individuals With Alzheimer Disease

Yaakov Stern, PhD; Min-Xing Tang, PhD; Marilyn S. Albert, PhD; Jason Brandt, PhD; Diane M. Jacobs, PhD; Karen Bell, MD; Karen Marder, MD; Mary Sano, PhD; Devangere Devanand, MD; Steven M. Albert, PhD; Frederick Bylsma, PhD; Wei-Yann Tsai, PhD

Objective.—To develop and validate an approach that uses clinical features that can be determined in a standard patient visit to estimate the length of time before an individual patient with Alzheimer disease (AD) requires equivalent to nursing home placement or dies.

Design.—Prospective cohort study of 236 patients, followed up semiannually for up to 7 years. A second validation cohort of 105 patients was also followed.

Setting.—Three AD research centers.

Patients.—All patients met National Institute of Neurological and Communicative Disorders and Stroke—Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD and had mild dementia at the initial visit.

Intervention.—Predictive features, ascertained at the initial visit, were sex, duration of illness, age at onset, modified Mini-Mental State Examination (mMMS) score, and the presence or absence of extrapyramidal signs or psychotic features.

Main Outcome Measures.—(1) Requiring the equivalent of nursing home placement and (2) death.

Results.—Prediction algorithms were constructed for the 2 outcomes based on Cox proportional hazard models. For each algorithm, a predictor index is calculated based on the status of each predictive feature at the initial visit. A table that specifies the number of months in which 25%, 50%, and 75% of patients with any specific predictor index value are likely to reach the end point is then consulted. Survival curves for time to need for care equivalent to nursing home placement and for time to death derived from the algorithms for selected predictor indexes fell within the 95% confidence bands of actual survival curves for patients. When the predictor variables from the initial visit for the validation cohort patients were entered into the algorithm, the predicted survival curves for time to death fell within the 95% confidence bands of actual survival curves for the patients.

Conclusions.—The prediction algorithms are a first but promising step toward providing specific prognoses to patients, families, and practitioners. This approach also has clear implications for the design and interpretation of clinical trials in patients with AD.

JAMA. 1997;277:806-812

Despite numerous advances in the biological study of Alzheimer disease (AD), we remain unable to reliably estimate the length of time from disease onset to important disease end points such as nursing home admission or death. Patients with AD and their families typically may inquire when to expect these end points, but it has not been possible provide an accurate, empirically based answer. The presence of extrapyramidal signs or psychosis and younger age at disease onset are associated with more rapid disease course. This article presents the development and validation of an approach that uses these clinical features to estimate the length of time before a patient requires nursing home care or dies. These algorithms represent the first attempt we know of to make such predictions for individual patients.

Methods

Subjects were members of the Predictors Study cohort. A total of 236 patients with probable AD were recruited at 5 sites: Columbia University College of Physicians and Surgeons, New York, NY; Johns Hopkins University School of Medicine, Baltimore, Md; and Massachusetts General Hospital, Boston. Inclusion and exclusion criteria, recruitment methods, and the full evaluation battery have been described. Each patient met National Institute of Neurological and Communicative Disorders and Stroke—Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD, with 1 exception described below. To ensure that severity of dementia was mild at study entry, all patients were required to have a modified Mini-Mental State Examination (mMMS) score of 30 or above (corresponding to approximately 10 on the standard Mini-Mental State Examination [MMSE]). To ensure accurate initial assessment of psychotic symptoms, all patients were required to not be treated with neuroleptic medications for at least 1 month prior to their initial evaluation. Exclusion criteria were history or current clinical evidence of substance abuse, schizophrenia, schizoaffective disorder, or major affective disorder prior to the onset of intellectual decline; any electroconvulsive therapy treatment within 2 years of recruitment, or 10 or more electroconvulsive treatments at any time; history

806 JAMA, March 12, 1997—Vol. 277, No. 10

Predictor Algorithms for Alzheimer Disease—Stern et al

From the Departments of Neurology (DrS. Stern, Tang, Jacobs, Bell, Marder, Sano, and S. M. Albert), Psychiatry (DrS. Stern and Devanand), and Biostatistics (Dr Tsai), and the Gertrude H. Sergievsky Center and Taub Center for Alzheimer’s Disease Research (DrS. Stern, Tang, Jacobs, Bell, Marder, Sano, and S. M. Albert), Columbia University College of Physicians and Surgeons, New York, NY; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Md (Dr S. Albert); and the Departments of Psychiatry and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass (Dr M. S. Albert). Reprints: Yaakov Stern, PhD, Sergievsky Center, 630 W 168th St, New York, NY 10032.
or clinical signs of stroke or a Hachinski Ischemic Score of 5 or more. Patients with small subcortical lesions on computed tomographic or magnetic resonance imaging scans that were clinically and historically silent and were judged to be less than 2 cm in diameter were included, as were those with diffuse symmetric periventricular lucencies. However, patients with cortical lesions of any size or location or with focal cortical atrophy in a specific vascular distribution were excluded.

This project was approved by the institutional review board at each participating institution, and all patients provided written informed consent.

Procedures

Predictors.—At the initial visit, the following predictive features were assessed:

**Duration of Illness.**—The clinician estimated disease duration based on interviews with the patient and informants. As part of the standard medical history, the clinician asked the informants to date the onset of clinical features such as memory, performance, and language changes in order to date the onset of the disease. Clinicians’ estimates were separately confirmed using a standardized interview technique.10

**Age at Onset.**—Based on this interview, age at onset of dementia was characterized as young (younger than 65 years) or old (age 65 years or older).

**Extrapyramidal Signs.**—Selected items from the Unified Parkinson’s Disease Rating Scale (UPDRS)11 were used to rate extrapyramidal signs. Hypophonia, masked faces, resting tremor, rigidity (neck and each limb), brady/hypokinesia, and posture and gait abnormalities were rated as absent, slight, mild to moderate, marked, or severe.12 Patients who had at least 1 sign rated as mild to moderate were considered to have extrapyramidal signs since ratings of this severity are more reliable and are apt to be noted by the average clinician.12 Our analyses focused on non-drug-induced extrapyramidal signs. If a patient’s signs were possibly or probably drug-induced, then they were not considered extrapyramidal signs for the purpose of prediction and were not included in the statistical analyses.

**Psychosis.**—A semistructured interview, the Columbia University Scale for Psychopathology in Alzheimer’s Disease (CUSP-A),14 was used to elicit information about delusions, hallucinations, and other specific behavioral signs occurring during the month prior to assessment. Specific delusions queried included paranoid delusions, delusions of abandonment, somatic delusions, and misidentifications. We used the presence of delusions or hallucinations at the initial visit as evidence of psychosis.

**Cognition.**—Cognitive function was examined using the mMMS,15 which includes the items from the standard MMSE,16 the Wechsler Adult Intelligence Scale—Revised (WAIS-R) Digit Span subtest,17 and additional attention/calculation, general knowledge, language, and construction items. The maximum score on the mMMS is 57.

Other measures were also obtained at each study visit, including the Blessed Dementia Rating Scale (BDRS) (Part 1)18 to assess functional capacity, and the Clinical Dementia Rating (CDR) Scale19 to rate the overall severity of the dementia.

Outcomes.—Patients were followed up semiannually for up to 7 years. The following 2 outcomes were considered.

**Health.**—The Health-Related Facility Care. The “equivalent institutional care”20 that the patient was receiving was rated at each 6-month follow-up interval. This rating summarizes the interviewer’s impression, based on data from the entire study protocol, of the care the patient received and required, regardless of the patient’s location. Categories are limited home care; adult home (a supervised setting with regular assistance in most activities); and health-related facility (nursing home care). We used the rating equivalent to care in a health facility as an end point for prediction since it is equivalent to nursing home placement, an important event for families of patients with AD. Interrater reliability for the equivalent care rating is good; the intraclass correlation coefficient was 0.73 in a study of 20 patients.21

**Death.**—Autopsies were obtained whenever possible. When autopsies were not obtained, we typically learned of patients’ deaths from family members or when attempting to complete follow-up visits. For patients who could not be contacted for follow-up or were otherwise unavailable for follow-up, death information was obtained as available through the National Death Index.

Validation Population.—A population was selected in which to assess the accuracy of the algorithm with respect to the death outcome. We used data from elders with dementia in North Manhattan who were being followed up prospectively as part of another epidemiologic study. None of these patients were members of the Predictors Study cohort. These patients also met NINCDS-ADRDA criteria for probable AD based on neurological examination, neuropsychological testing, and functional evaluation. Duration of illness, extrapyramidal signs, and mortality information were collected as described above. The mMMS was not administered to this population, so we developed a regression equation to estimate mMMS scores on the basis of 2 tests they did receive, the short Blessed test22 and total recall on the Selective Reminding Test.23 The equation was based on a group of 255 probable AD patients who took all 3 tests. The multiple R for the regression equation was 0.72. Patients were included in the validation analysis if the UPDRS, duration of illness estimates, and data required to estimate the mMMS score were available and if the estimated mMMS was at least 25. This provided 105 patients for the current analyses.

**Apolipoprotein E.**—Apolipoprotein E (APOE) studies were not an original component of this study. However, we wanted to determine whether APOE genotype influenced the prediction algorithms that were developed. Beginning in the sixth year of the study, available subjects were approached to contribute blood samples for analysis. In addition, analyses were conducted on frozen brain tissue of 12 patients who had died and contributed their brains for postmortem studies.

The pattern of each subject’s APOE isoforms was determined using the method of Hixson and Vernier.24 The white blood cells were isolated from fresh blood samples after centrifugation at 2000 rpm for 20 minutes at 4°C, and the DNA was digested with HhaI. Leukocyte DNA was amplified by polymerase chain reaction (PCR) using specifically synthesized oligonucleotide primers and Taq polymerase. The amplified APOE products were then digested with 5 units of HaAl enzyme at 37°C for 4 hours. The digest was electrophoresed on a 12% nondenaturing polyacrylamide gel for 3 hours at a constant current of 10 mA. The gels were then treated with ethidium bromide for 10 to 15 minutes, and the DNA fragments were visualized by ultraviolet illumination. Fragments of DNA of known size were used as markers.

Data Analyses

**Cox Analyses.**—Cox proportional hazard analyses used the predictors listed above: extrapyramidal signs, psychosis, and age at onset. Initial mMMS score, estimated duration of illness, and sex were also considered as potential covariates. Since older patients might reach the defined end points sooner, all Cox analyses were stratified by the median age at first visit, 73 years.

Reaching the equivalent of nursing home care and death were the 2 outcomes considered. For each outcome, we calculated a Cox proportional hazards model that used months from the initial visit as the timing variable. After calculating each model, it was “trimmed back” to include only those covariates that were associ-
Table 1.—Cox Proportional Hazard Analysis Predicting Reaching an Institutional Care Rating Equivalent to Health-Related Facility Care

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Hazard Ratio (95% CI)</th>
<th>β</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS present</td>
<td>2.56 (1.49-4.41)</td>
<td>0.9419</td>
<td></td>
</tr>
<tr>
<td>Psychotic symptoms present</td>
<td>1.50 (1.04-2.15)</td>
<td>0.4027</td>
<td></td>
</tr>
<tr>
<td>Young age at onset, &lt;65 y</td>
<td>1.62 (0.92-2.67)</td>
<td>0.4848</td>
<td></td>
</tr>
<tr>
<td>mMMS score (each unit)</td>
<td>0.93 (0.90-0.96)</td>
<td>-0.0724</td>
<td></td>
</tr>
<tr>
<td>Duration of illness, y</td>
<td>0.94 (0.87-1.01)</td>
<td>0.0617</td>
<td></td>
</tr>
</tbody>
</table>

*RR indicates relative risk; CI, confidence interval; EPS, extrapyramidal signs; and mMMS, modified Mini-Mental State Examination.*

Table 2.—Guide for Calculating a Patient's Predictor Index for Health-Related Facility Care

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Coding</th>
<th>Value</th>
<th>Weight</th>
<th>Value × Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS</td>
<td>0</td>
<td>Absent, 1 present</td>
<td>×</td>
<td>−0.9419</td>
</tr>
<tr>
<td>Psychotic symptoms</td>
<td>0</td>
<td>Absent, 1 present</td>
<td>×</td>
<td>−0.4027</td>
</tr>
<tr>
<td>Age at onset</td>
<td>0</td>
<td>Normal, 1 young (&lt;65 y)</td>
<td>×</td>
<td>−0.4848</td>
</tr>
<tr>
<td>mMMS</td>
<td>Actual score</td>
<td>×</td>
<td>0.0724</td>
<td></td>
</tr>
<tr>
<td>Duration of illness</td>
<td>Estimated years</td>
<td>×</td>
<td>0.0617</td>
<td></td>
</tr>
</tbody>
</table>

Table 3.—Specific Prediction of Months Until a Patient Will Require Health-Related Facility Care, Based on Predictor Index*

<table>
<thead>
<tr>
<th>HRF Care index</th>
<th>Young (&lt;73 y)</th>
<th>Old (&gt;73 y)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>25%</td>
<td>50%</td>
</tr>
<tr>
<td>1.0</td>
<td>12.2</td>
<td>16.9</td>
</tr>
<tr>
<td>1.2</td>
<td>13.1</td>
<td>18.9</td>
</tr>
<tr>
<td>1.4</td>
<td>13.1</td>
<td>21.2</td>
</tr>
<tr>
<td>1.6</td>
<td>14.9</td>
<td>24.3</td>
</tr>
<tr>
<td>1.8</td>
<td>16.8</td>
<td>25.9</td>
</tr>
<tr>
<td>2.0</td>
<td>18.3</td>
<td>29.7</td>
</tr>
<tr>
<td>2.2</td>
<td>20.2</td>
<td>34.0</td>
</tr>
<tr>
<td>2.4</td>
<td>22.7</td>
<td>36.8</td>
</tr>
<tr>
<td>2.6</td>
<td>24.7</td>
<td>41.4</td>
</tr>
<tr>
<td>2.8</td>
<td>29.2</td>
<td>43.9</td>
</tr>
<tr>
<td>3.0</td>
<td>31.1</td>
<td>49.9</td>
</tr>
<tr>
<td>3.2</td>
<td>36.3</td>
<td>53.5</td>
</tr>
<tr>
<td>3.4</td>
<td>38.2</td>
<td>56.6</td>
</tr>
<tr>
<td>3.6</td>
<td>42.6</td>
<td>60.7</td>
</tr>
<tr>
<td>3.8</td>
<td>47.8</td>
<td>67.1</td>
</tr>
</tbody>
</table>

*For each predictor index value (as calculated in Table 2), the table shows number of months within which the specified percentage of comparable patients require the equivalent of health-related facility (HRF) care. Values for younger (<73 years) and older (>73 years) patients are provided separately. Empty cells represent patients with milder severity at their initial visit (and thus higher predictor index values) for whom there are insufficient data to generate predictions.*

RESULTS

Mean (SD) age of the 236 patients at intake into the study was 73.1 (8.9) years. Mean estimated duration of illness was 3.9 (2.4) years. There were 96 men and 140 women; 84% of the group were non-Hispanic whites. Mean mMMS at intake was 37.9 (5.6), mean BDRS was 8.0 (3.5), and mean CDR was 1.1 (0.3), all consistent with mild disease severity. Medical conditions and medications at intake have been summarized previously.7 Of the 236 patients, 25% were taking antihypertensive medications; 9%, antidepressants; 6%, sedative hypnotics; 5%, thyroid medication; and 6% of patients were taking more than 1 of these medications. Abnormal findings on medical evaluation were identified in 25%, but none of these was felt to contribute to the presentation of dementia.
At baseline, 26 patients (11%) had at least 1 extrapyramidal sign that was rated in the mild to moderate range and was not drug induced; 15 patients had extrapyramidal signs that were or might have been drug induced and were excluded from the analyses; and 103 patients had at least 1 psychotic feature. Age at onset was considered young (< 65 years) in 34 patients. At the time of these analyses, 220 patients were followed up for 1 or more years, 199 for 2 or more years, 164 for 3 or more years, 138 for 4 or more years, 94 for 5 or more years, and 43 for 6 or more years. Maximum follow-up time at this point is 7 years.

**Health Related Facility Care**

Over the follow-up period, 164 patients were judged to have reached the point where they received the equivalent of health related facility care. Of these, 63 were actually admitted to a nursing home at the same time and another 34 were admitted sometime later. No subject was admitted to a nursing home without being judged as requiring that care. Using t tests, we compared the scores on several indexes of dementia severity among patients who were and were not admitted to a nursing home at the point that they were first rated as requiring the equivalent of nursing home care. The 2 groups did not differ significantly in level of cognitive dysfunction as assessed by the mMMS (mean mMMS=20.3 [11.6] and 22.3 [13.9], respectively); functional disability as assessed by total score on the BDRS (mean BDRS=15.0 [3.8] and 15.1 [5.3], respectively); basic activities of daily living as assessed by the BDRS (mean score=3.2 [2.2] and 3.5 [3.1], respectively); and overall dementia severity as rated by the CDR (mean CDR=2.1 [0.7] and 2.2 [0.9], respectively).

Results of the Cox analysis are summarized in Table 1. The relative risk (RR) of reaching this endpoint was significantly increased in patients who had extrapyramidal signs or psychotic symptoms at their initial visit and in patients with young age at disease onset. Higher mMMS scores were associated with significantly reduced risk of reaching the endpoint, and a similar trend was noted for longer estimated disease duration at the initial visit. The sex of the patient was not a significant predictor of nursing home level care.

In order to check the assumptions of the Cox regression model, we plotted the martingale residuals against months of follow-up. All but 4 subjects fell within the predicted horizontal band around 0, satisfying the assumptions of proportional hazards. In supplementary analysis, we compared the Cox models calculated for each separately. Results were compatible across the 3 sites.

Based on the β weights, a formula was developed to calculate the predictor index for nursing home level care. The formula and its calculation are summarized in Table 2.

Table 3 summarizes the number of months from intake that 25%, 50%, and 75% of subjects with a particular predictor index would be expected to require nursing home care. Note that a lower predictor index is associated with the worst prognoses, while higher values are progressively associated with better prognoses.

Figure 1 displays the comparisons between the survival curves generated from the prediction algorithm for predictor indexes of 2.3, and 4 and survival curves of patients whose initial visit was within 0.5 unit of this
value. The curves generated from the algorithms almost always fall within the 95% confidence bands of the curves generated from the data.

**Mortality**

There were 99 deaths. In the Cox analyses there was a significantly reduced mortality RR for women and for patients with longer duration of illness. A similar trend was noted for patients with higher mMMS scores. There was a significantly increased mortality RR associated with the presence of extrapyramidal signs (Table 4). Psychosis and age at onset were not significant predictors.

To check the assumptions of the Cox regression model, we plotted the martingale residuals against months of follow-up. All subjects fell within the predicted horizontal bands, around 0, satisfying the assumptions of proportional hazards. In supplementary analyses, we compared the Cox models calculated for each separately. Results were compatible across the 5 sites.

Based on the 

Table 5.-Guide for Calculating a Patient’s Predictor Index for Death *

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Coding</th>
<th>Value</th>
<th>Weight</th>
<th>Value × Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Male</td>
<td>0</td>
<td>0.7046</td>
<td></td>
</tr>
<tr>
<td>EPS</td>
<td>Absent</td>
<td>0</td>
<td>-1.2825</td>
<td></td>
</tr>
<tr>
<td>mMMS</td>
<td>Actual score</td>
<td>0</td>
<td>0.0310</td>
<td></td>
</tr>
</tbody>
</table>

Death predictor index (sum) = 

3 years’ duration of illness. Current mMMS score is 46; no extrapyramidal signs or psychosis is noted at the current evaluation. Based on Table 2, the predictor index for nursing home care is 3.4. Using the “Old” (age >73 years) column in Table 3, this patient can be told that 25% of similar patients require nursing home care within 29 months and 50% within 49 months. Based on Table 5, the predictor index for death is 2.4. Using the “Old” (age >73 years) column in Table 6, this patient can be told that 25% of similar patients die within 60 months, 50% within 73 months, and 75% within 80 months.

**Validation Population**

Mean age at first visit of the validation population was 82.5 (6.9) years. Mean estimated duration of illness was 3.4 (6.8) years. There were 15 men and 90 women. Mean estimated mMMS at intake was 31.8 (4.5). At their initial visit, 30 patients had at least 1 extrapyramidal sign that was rated in the mild to moderate range and was not drug induced. There were 83 deaths.

All subjects were aged 73 years or older at the initial visit, so prediction of time to death was derived from the “Old” column on Table 6. Figure 3 presents the survival curve and its 95% confidence band for the subjects’ 2 index ranges, along with the survival curve generated from the predictor model for the predictor index of the median of each range. In both cases, the predicted survival falls well within the 95% confidence bands of the actual survival curves.

**Apolipoprotein E**

The APOE genotypes were obtained for 101 of the subjects from a pool of approximately 150 for whom they were potentially available. For the purpose of analysis, patients were dichotomized into 2 groups, those with (n=58) and those without (n=43) at least 1 e4 allele. The stratified APOE genotype variable was
then introduced into the Cox models that were used to generate the prediction algorithms.

In the Cox model, having at least 1 e4 allele was associated with an RR of 0.69 for reaching the nursing home care outcome (95% confidence interval [CI], 0.38-1.26). The RRs associated with the other predictors remained comparable to those in the original model. Having at least 1 e4 allele was associated with mortality RR of 0.56 (95% CI, 0.27-1.0). The RRs associated with the other predictors remained comparable to those in the original model.

**Postmortem Diagnosis**

Autopsies were obtained for 44 of the 99 patients who died. Of these 44 patients, 37 had AD, 4 had senile changes of the Alzheimer type (1 with concomitant progressive subcortical gliosis), 1 had diffuse Lewy body disease, 1 had hippocampal sclerosis, and 1 had a slowly progressive form of Creutzfeldt-Jakob disease.

**COMMENT**

Prognosis is a standard part of a medical evaluation, and it is possible to predict outcomes for many medical conditions. However, these predictions have not been available for patients with AD. As with any other disease, prediction rests on the identification of specific disease features that impart prognostic information. We used several clinical features that have been reliably associated with disease course and are readily ascertainable in a clinical setting to develop predictor algorithms for AD.

The algorithms described here apply best to patients similar to those included in our study. The study was derived from patients seen at specialized AD centers, who met research criteria for PAD with mild to moderate disease severity and were ambulatory. Patients with more complex medical histories and specific systemic illnesses may not fit the predictor model in the same way. We restricted the algorithms to the range of predictor indexes actually seen in our cohort at their initial visit.

We validated and cross-validated the accuracy of the algorithms’ predictions, but they will benefit from further development and validation. Replication and confirmation of the algorithms in other populations will increase accuracy. Still, this approach can differentiate patients with better and worse prognoses to a degree that is not currently possible.

One encouraging feature of the cross-validation analysis was that an estimated mMMS score derived from a regression analysis was a useful proxy for the actual score in the equation to derive the predictor index. We have derived equations for estimating mMMS scores from...
other mental status scale scores including the standard MMSE60 (for example, mMMS = 1.73 MMSE = 2.81), and this should broaden the applicability of the predictor algorithms to patients at different clinical centers.

Rather than using actual entry into nursing home care as a study end point, we chose to use the point at which the patient began to receive the equivalent of this care. We chose this approach because the cause of death is attributed to a patient to nursing home care is influenced by a range of nonmedical factors including financial, cultural, and familial considerations. In some cases the family may elect to provide the equivalent of nursing home level care in the home. The equivalent institutional care rating that we used was based on the entire range of instruments used in the semiannuall evaluations, including several measures of activities of daily living and a measure of patient dependence.60 Patients who reached this end point scored comparably on a range of cognitive and functional measures whether or not they were actually placed in a facility. We therefore feel predicting this outcome is more useful for clinicians, patients, and their families.

The current algorithm does not consider the cause of death or the presence of other medical conditions that might contribute differentially to mortality. In adherence with NINCDS-ADREA criteria for the diagnosis of AD, patients' neurological examinations were notable only for mental status changes but were otherwise unremarkable, and none had medical conditions that would contribute to their dementia. None of the patients had a life threatening illness at study entry. We chose to exclude medical conditions that might arise during follow-up from the algorithm because there is no systematic way to predict their occurrence at the initial visit. Comparative to the experience in other clinical centers where diagnostic criteria are strictly applied, postmortem data suggest that our diagnostic accuracy was relatively high. Of the 44 autopsies performed, 37 confirmed AD and another 4 found "senile changes of the Alzheimer type," which indicate AD-like changes that are out of the range of normal aging but are of insufficient severity or distribution to make the diagnosis of AD. We chose not to eliminate patients without confirmed AD from our analyses for several reasons. First, we acquired autopsies for only half of the patients who died. It would be inconsistent to selectively eliminate cases only from the autopsyed group. Second, all of the patients met the standard clinical criteria typically used at AD research centers and were representative of the patients followed up in most AD cohorts.

Thus, the presented algorithms are derived from and useful for the typical patients diagnosed with AD. Since the final diagnosis is not available of a patient at an initial visit, we argue that it should not influence the prediction algorithm.

Patients with a longer estimated duration of symptoms at their initial visit had a better prognosis. Thus, in 2 patients with comparable disease severity, longer duration of illness is actually an indicator of a more benign disease course. This relationship between estimated duration of illness and prognosis has been noted in other diseases as well.25 Because the presence of the APOE e4 allele is associated with earlier onset of AD, it is possible that disease progression might also be more rapid. However, reports to date have not supported this possibility,26 and some have suggested a trend toward slower disease progression in patients with 1 or more e4 alleles.25,26 Our data also suggest that survival was better in patients with at least 1 e4 allele, but the RR in the current model was not significant. Although APOE status may eventually prove to have some predictive value for disease course, we chose to exclude it from the prediction algorithms because the relationship between APOE genotype and disease progression has not been established, and the algorithms will have greater clinical utility if they rely on clinical signs that are readily ascertained at a patient visit.

We propose these prediction algorithms as a first but promising step toward providing important information about the expected time until disease outcomes to patients, families, and practitioners. In addition to its prognostic value in a clinical setting, this approach may facilitate design and interpretation of clinical trials in patients with AD by providing an expected time course to the equivalent of nursing home placement and death with which the patient's actual course can be compared.

This study was supported by grants AG07370, AG07323, RR00645, from the NIH and by the Charles S. Robertson Gift for Alzheimer's Disease and the Charles S. Robertson Gift for Alzheimer's Disease Research. We thank W. Allen Hauser, MD, for his guidance in implementing this study.

References